BIOSTAR PHARM-B Receives CSRC Filing Notice for Full Circulation of H Shares

Stock News

02/06

BIOSTAR PHARM-B (02563) has announced that the company received a filing notice from the China Securities Regulatory Commission (CSRC) dated February 5, 2026. According to the notice, the company has completed the filing with the CSRC for the implementation of a full circulation of its H shares. The filing notice will be valid for 12 months from its date of issue. The company will apply to the Stock Exchange of Hong Kong for the conversion and listing of the shares. As of the date of this announcement, the specific details of the implementation plan for the conversion and listing have not been finalized. The company will issue further announcements regarding the progress and details of the conversion and listing at the appropriate time, in accordance with the Listing Rules and applicable laws.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1189658924"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1189658924\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1189658924?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-06 22:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1189658924","market":"hk","top_or_hot":-1,"title":"BIOSTAR PHARM-B Receives CSRC Filing Notice for Full Circulation of H Shares","media":"Stock News","content":"<p>BIOSTAR PHARM-B (02563) has announced that the company received a filing notice from the China Securities Regulatory Commission (CSRC) dated February 5, 2026. According to the notice, the company has completed the filing with the CSRC for the implementation of a full circulation of its H shares. The filing notice will be valid for 12 months from its date of issue. The company will apply to the Stock Exchange of Hong Kong for the conversion and listing of the shares. As of the date of this announcement, the specific details of the implementation plan for the conversion and listing have not been finalized. The company will issue further announcements regarding the progress and details of the conversion and listing at the appropriate time, in accordance with the Listing Rules and applicable laws.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BIOSTAR PHARM-B Receives CSRC Filing Notice for Full Circulation of H Shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBIOSTAR PHARM-B Receives CSRC Filing Notice for Full Circulation of H Shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-02-06 22:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BIOSTAR PHARM-B (02563) has announced that the company received a filing notice from the China Securities Regulatory Commission (CSRC) dated February 5, 2026. According to the notice, the company has completed the filing with the CSRC for the implementation of a full circulation of its H shares. The filing notice will be valid for 12 months from its date of issue. The company will apply to the Stock Exchange of Hong Kong for the conversion and listing of the shares. As of the date of this announcement, the specific details of the implementation plan for the conversion and listing have not been finalized. The company will issue further announcements regarding the progress and details of the conversion and listing at the appropriate time, in accordance with the Listing Rules and applicable laws.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1515","symbol_name":"抗疫概念","start_time":0,"source_url":"","article_id":"1189658924","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1189658924","pubTimestamp":1770389534,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"BIOSTAR PHARM-B (02563) has announced that the company received a filing notice from the China Securities Regulatory Commission (CSRC) dated February 5, 2026. According to the notice, the company has...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","BK1515":"抗疫概念","BK1161":"生物科技","BK1574":"生物医药B类股","02563":"华昊中天医药-B","09939":"开拓药业-B"},"translate_title":"映泰医药-B收到证监会H股全流通备案通知书","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"09939":1,"02563":1},"content_text":"BIOSTAR PHARM-B (02563) has announced that the company received a filing notice from the China Securities Regulatory Commission (CSRC) dated February 5, 2026. According to the notice, the company has completed the filing with the CSRC for the implementation of a full circulation of its H shares. The filing notice will be valid for 12 months from its date of issue. The company will apply to the Stock Exchange of Hong Kong for the conversion and listing of the shares. As of the date of this announcement, the specific details of the implementation plan for the conversion and listing have not been finalized. The company will issue further announcements regarding the progress and details of the conversion and listing at the appropriate time, in accordance with the Listing Rules and applicable laws.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}